公开(公告)号：US08741957B2

公开(公告)日：2014-06-03

申请号：US12304455

申请日：2007-06-13

申请人： Patricia Salvati ,  Stefano Rossetti ,  Luca Benatti

发明人： Patricia Salvati ,  Stefano Rossetti ,  Luca Benatti

IPC分类号： A61K31/165 ,  A61K31/404 ,  A61K31/085 ,  A61K31/135 ,  A61K31/341 ,  A61K31/402

CPC分类号： A61K31/404 ,  A61K31/085 ,  A61K31/135 ,  A61K31/165 ,  A61K31/341 ,  A61K31/402

摘要： The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening.

摘要翻译： 本发明通过给予α-氨基酰胺，特别是safinamide，在学习和记忆中的认知缺陷的药物治疗领域。 可以用本发明化合物治疗的认知障碍的例子是与自闭症，阅读困难，注意缺陷多动障碍，精神分裂症，强迫症，精神病，双相情感障碍，抑郁症，Tourette综合征，轻度认知障碍 （MCI）和儿童，青少年和成年人学习障碍，年龄相关记忆障碍，年龄相关认知衰退，阿尔茨海默病，帕金森病，唐氏综合征，创伤性脑损伤亨廷顿病，进行性核核麻痹（PSP），艾滋病毒，中风， 血管疾病，Pick's或Creutzfeldt-Jacob疾病，多发性硬化症（MS），其他白质病症和药物诱导的认知恶化。

公开(公告)号：US20100016437A1

公开(公告)日：2010-01-21

申请号：US12304455

申请日：2007-06-13

申请人： Patricia Salvati ,  Stefano Rossetti ,  Luca Benatti

发明人： Patricia Salvati ,  Stefano Rossetti ,  Luca Benatti

IPC分类号： A61K31/195 ,  A61K31/165 ,  A61P25/00

CPC分类号： A61K31/404 ,  A61K31/085 ,  A61K31/135 ,  A61K31/165 ,  A61K31/341 ,  A61K31/402

摘要： The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening.

摘要翻译： 本发明通过施用α-氨基酰胺，特别是safinamide，在学习和记忆中的认知缺陷的药物治疗领域。 可以用本发明化合物治疗的认知障碍的例子是与自闭症，阅读困难，注意缺陷多动障碍，精神分裂症，强迫症，精神病，双相情感障碍，抑郁症，Tourette综合征，轻度认知障碍 （MCI）和儿童，青少年和成年人学习障碍，年龄相关记忆障碍，年龄相关认知衰退，阿尔茨海默病，帕金森病，唐氏综合征，创伤性脑损伤亨廷顿病，进行性核核麻痹（PSP），艾滋病毒，中风， 血管疾病，Pick's或Creutzfeldt-Jacob疾病，多发性硬化症（MS），其他白质病症和药物诱导的认知恶化。